Last reviewed · How we verify

BIIB059 (litifilimab) — Competitive Intelligence Brief

BIIB059 (litifilimab) (BIIB059 (litifilimab)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune checkpoint inhibitor (B7-related protein 1 antagonist). Area: Immunology.

phase 3 Immune checkpoint inhibitor (B7-related protein 1 antagonist) BR1 (B7-related protein 1) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

BIIB059 (litifilimab) (BIIB059 (litifilimab)) — Biogen. Litifilimab is a monoclonal antibody that blocks B7-related protein 1 (BR1), an immune checkpoint molecule that suppresses T cell activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BIIB059 (litifilimab) TARGET BIIB059 (litifilimab) Biogen phase 3 Immune checkpoint inhibitor (B7-related protein 1 antagonist) BR1 (B7-related protein 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune checkpoint inhibitor (B7-related protein 1 antagonist) class)

  1. Biogen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BIIB059 (litifilimab) — Competitive Intelligence Brief. https://druglandscape.com/ci/biib059-litifilimab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: